hemotune AG is a globally leading magnetic nanoparticle technology platform based in Schlieren, Switzerland. By combining nanotechnology with advanced engineering, hemotune develops scalable, highly selective, and efficient solutions for the extraction of biomolecules from complex fluids. The company’s therapeutic platform is poised to enter clinical development following proof-of-concept in indications with high unmet medical needs - including a combination gene therapy program, selectively targeting anti-AAV antibodies for safer, and more efficacious gene therapies.

Building on the platform’s precision, modularity, and scalability, hemotune is actively expanding into new high-potential areas — developing innovative solutions to support cell and gene therapy workflows and tackle critical challenges in biopharmaceutical manufacturing, such as targeted impurity removal, and process optimization.

hemotune AG is committed to pushing the boundaries of healthcare and delivering transformative manufacturing solutions that have the potential to redefine patient care worldwide. For more information, please visit www.hemotune.ch